Pharma swarm on obesity

Obesity drugs work by turning down hunger signals that normally keep telling the brain to eat again. The two biggest sellers today, Wegovy from Novo Nordisk and Zepbound from Eli Lilly, mimic gut hormones that slow stomach emptying and increase fullness after meals. (accessdata.fda.gov) That basic trick turned into a commercial stampede after the drugs started producing weight loss numbers that looked closer to surgery than to older diet pills. In the New England Journal of Medicine, Lilly’s SURMOUNT-1 trial reported average weight reductions of 19.5% and 20.9% at the 10 milligram and 15 milligram tirzepatide doses over 72 weeks. (nejm.org) The field got even hotter when obesity drugs stopped looking like vanity products and started looking like heart drugs too. Novo Nordisk’s SELECT trial showed semaglutide 2.4 milligrams cut major adverse cardiovascular events by 20% in adults with overweight or obesity and prior cardiovascular disease who did not have diabetes. (novonordiskmedical.com) That is why more than 80 companies are now crowding into the pipeline. DelveInsight’s 2026 obesity pipeline report says the field now includes 80-plus companies and 100-plus drug candidates across clinical and nonclinical stages. (delveinsight.com) The next fight is not just about stronger weight loss. It is about making these drugs easier to take, which is why companies are racing from weekly shots toward daily pills. (prnewswire.com) Novo Nordisk got there first in the United States with a Wegovy pill approved on December 22, 2025. Eli Lilly answered on April 1, 2026, when the Food and Drug Administration approved its oral obesity drug orforglipron, branded Foundayo. (prnewswire.com) (biopharmadive.com) Another lane is combination therapy, which works like using two dimmer switches instead of one. Roche and Zealand Pharma announced a March 11, 2025 deal to co-develop petrelintide, an amylin-based obesity drug, with Roche’s incretin candidate CT-388. (roche.com) Amylin is a different hormone signal from the glucagon-like peptide 1 signal used by Wegovy and many rivals. Zealand says the petrelintide and CT-388 pairing is aimed at people who need more weight loss or better blood sugar control than amylin alone can provide. (zealandpharma.com) The market is also widening beyond weight itself into obesity-linked diseases that insurers and doctors already spend billions treating. Zepbound’s current label includes moderate to severe obstructive sleep apnea in adults with obesity, which gives drugmakers another route to win coverage and prescribing volume. (pi.lilly.com) So this is no longer a two-company race built around one hormone and one injection pen. It is becoming a full drug platform war over pills versus shots, single hormones versus combinations, and obesity treatment versus heart disease, sleep apnea, and other complications tied to excess weight. (delveinsight.com) (accessdata.fda.gov)